IBD prevalence in Lothian, Scotland, derived by capture-recapture methodology
Gareth-Rhys Jones, Mathew Lyons, Nikolas Plevris, Philip W Jenkinson, Cathy Bisset, Christopher Burgess, Shahida Din, James Fulforth, Paul Henderson, Gwo-Tzer Ho, Kathryn Kirkwood, Colin Noble, Alan G Shand, David C Wilson, Ian Dr Arnott, Charlie W Lees, Gareth-Rhys Jones, Mathew Lyons, Nikolas Plevris, Philip W Jenkinson, Cathy Bisset, Christopher Burgess, Shahida Din, James Fulforth, Paul Henderson, Gwo-Tzer Ho, Kathryn Kirkwood, Colin Noble, Alan G Shand, David C Wilson, Ian Dr Arnott, Charlie W Lees
Abstract
Objective: IBD prevalence is estimated to be rising, but no detailed, recent UK data are available. The last reported prevalence estimate in the UK was 0.40% in 2003. We aimed to establish the current, and project future, prevalence in Lothian, Scotland.
Design: We conducted an all-age multiparameter search strategy using inpatient IBD international classification of disease (ICD-10) coding (K50/51)(1997-2018), IBD pathology coding (1990-2018), primary and secondary care prescribing data (2009-2018) and a paediatric registry, (1997-2018) to identify 'possible' IBD cases up to 31/08/2018. Diagnoses were manually confirmed through electronic health record review as per Lennard-Jones/Porto criteria. Autoregressive integrated moving average (ARIMA) regression was applied to forecast prevalence to 01/08/2028.
Results: In total, 24 601 possible IBD cases were identified of which 10 499 were true positives. The point prevalence for IBD in Lothian on 31/08/2018 was 784/100 000 (UC 432/100 000, Crohn's disease 284/100 000 and IBD unclassified (IBDU) 68/100 000). Capture-recapture methods identified an additional 427 'missed' cases (95% CI 383 to 477) resulting in a 'true' prevalence of 832/100 000 (95% CI 827 to 837).Prevalence increased by 4.3% per year between 2008 and 2018 (95% CI +3.7 to +4.9%, p<0.0001). ARIMA modelling projected a point prevalence on 01/08/2028 of 1.02% (95% CI 0.97% to 1.07%) that will affect an estimated 1.53% (95% CI 1.37% to 1.69%) of those >80 years of age.
Conclusions: We report a rigorously validated IBD cohort with all-age point prevalence on 31/08/2018 of 1 in 125, one of the highest worldwide.
Keywords: Crohn’s disease; epidemiology; inflammatory bowel disease; ulcerative colitis.
Conflict of interest statement
Competing interests: NP has received consultancy fees from Takeda and speaker fees and travel support from AbbVie, Takeda and Norgine. SD has received travel support from AbbVie, Dr Falk and consultancy fees from Takeda. AGS has received travel support from AbbVie and Ferring. IA has received consultancy fees from Vifor and travel support from Takeda and Dr Falk. CWL has received research support from Gilead, Oshi Health and AbbVie, consultancy fees from AbbVie, Pfizer, Dr Falk, Hospira, MSD, Gilead, Pharmacosmos, Takeda and Vifor, and speaker fees and travel support from AbbVie, Pfizer, Ferring, Hospira and Takeda. GRJ, PWJ, ML, JF and GTH have no personal interests to declare. PH and SD are supported by an NHS Research Scotland Career Researcher Fellowship. DCW has received consultancy fees, speaker fees and/or travel support from Abbvie, Takeda, Roche, Ferring, Predictimmune, Dr Falk and 4D Pharma.
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ.
Figures
References
- Coward S, Clement F, Benchimol EI, et al. . Past and future burden of inflammatory bowel diseases based on modeling of population-based data. Gastroenterology 2019;156:1345–53. 10.1053/j.gastro.2019.01.002
- Ng SC, Shi HY, Hamidi N, et al. . Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2018;390:2769–78. 10.1016/S0140-6736(17)32448-0
- Rubin GP, Hungin AP, Kelly PJ, et al. . Inflammatory bowel disease: epidemiology and management in an English general practice population. Aliment Pharmacol Ther 2000;14:1553–9. 10.1046/j.1365-2036.2000.00886.x
- Stone MA, Mayberry JF, Baker R. Prevalence and management of inflammatory bowel disease: a cross-sectional study from central England. Eur J Gastroenterol Hepatol 2003;15:1275–80. 10.1097/01.meg.0000085500.01212.e2
- Nimmons D, Limdi JK. Elderly patients and inflammatory bowel disease. World J Gastrointest Pharmacol Ther 2016;7:51–65. 10.4292/wjgpt.v7.i1.51
- Ismail AA, Beeching NJ, Gill GV, et al. . How many data sources are needed to determine diabetes prevalence by capture-recapture? Int J Epidemiol 2000;29:536–41. 10.1093/intjepid/29.3.536
- von Elm E, Altman DG, Egger M, et al. . The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008;61:344–9. 10.1016/j.jclinepi.2007.11.008
- Everhov ÅH, Halfvarson J, Myrelid P, et al. . Incidence and treatment of patients diagnosed with inflammatory bowel diseases at 60 years or older in Sweden. Gastroenterology 2018;154:518–28. 10.1053/j.gastro.2017.10.034
- van der Have M, Mangen M-JJ, van der Valk ME, et al. . Effect of aging on healthcare costs of inflammatory bowel disease. Inflamm Bowel Dis 2014;20:637–45. 10.1097/01.MIB.0000442677.55051.03
- Colombel JF, Panaccione R, Bossuyt P, et al. . Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet 2018;390:2779–89. 10.1016/S0140-6736(17)32641-7
- Sturm A, Maaser C, Mendall M, et al. . European Crohn’s and Colitis organisation topical review on IBD in the Elderly. J Crohns Colitis 2017;11:263–73. 10.1093/ecco-jcc/jjw188
- Hanauer SB, Feagan BG, Lichtenstein GR, et al. . Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002;359:1541–9. 10.1016/S0140-6736(02)08512-4
- Colombel JF, Sandborn WJ, Reinisch W, et al. . Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 2010;362:1383–95. 10.1056/NEJMoa0904492
- Colombel JF, Sandborn WJ, Rutgeerts P, et al. . Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 2007;132:52–65. 10.1053/j.gastro.2006.11.041
- Fulop T, Larbi A, Dupuis G, et al. . Immunosenescence and inflamm-aging as two sides of the same coin: friends or foes? Front Immunol 2017;8:8 10.3389/fimmu.2017.01960
- Juneja M, Baidoo L, Schwartz MB, et al. . Geriatric inflammatory bowel disease: phenotypic presentation, treatment patterns, nutritional status, outcomes, and comorbidity. Dig Dis Sci 2012;57:2408–15. 10.1007/s10620-012-2083-x
- Moayyedi P, Tepper J, Hilsden R, et al. . International comparisons of manpower in gastroenterology. Am J Gastroenterol 2007;102:478–81. 10.1111/j.1572-0241.2006.00973.x
Source: PubMed